Skip to main content
Erschienen in: International Urology and Nephrology 1/2018

25.10.2017 | Nephrology - Original Paper

The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study

verfasst von: Naikuan Fu, Shicheng Yang, Jing Zhang, Peng Zhang, Min Liang, Hongliang Cong, Wenhua Lin, Fengshi Tian, Chengzhi Lu

Erschienen in: International Urology and Nephrology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the preventive effect of probucol combined with hydration on contrast-induced nephropathy (CIN) in patients with coronary heart disease undergoing percutaneous coronary intervention (PCI).

Methods

A total of 641 patients undergoing PCI were randomly assigned to either a probucol group (probucol 500 mg twice daily and hydration; n = 321) or a control group (hydration only; n = 320). The primary endpoint was the incidence of CIN, defined as an increase in serum creatinine (Scr) by ≥ 44.2 μmol/L or ≥ 25% within 72 h after the administration of contrast agent. Secondary endpoints were changes in Scr, cystatin-C (Cys-C), creatinine clearance rate (Ccr), C-reactive protein (CRP), superoxide dismutase (SOD), and glutathione (GSH) within 72 h, and major adverse events during hospitalization or the 14-day follow-up period.

Results

The incidence of CIN was 4.0% (13/321) in the probucol group and 10.9% (35/320) in the control group. The probucol group had lower Cys-C and higher Ccr at 48 and 72 h after PCI compared with the control group. At 48 and 72 h following the operation, Cys-C and CRP were lower in the probucol group compared with the control group, but Ccr, SOD, and GSH were higher. There were no differences in the incidence of major adverse events during hospitalization or the 14-day follow-up between the groups. Multivariate logistic regression analysis showed that probucol was an independent protective factor for CIN.

Conclusions

Probucol combined with hydration more effectively decreased the incidence of CIN in patients with coronary heart disease undergoing PCI compared with hydration alone.
Literatur
1.
Zurück zum Zitat Wang J, Ai X, Li L, Gao Y, Sun N, Li C, Sun W (2017) Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. Int Urol Nephrol. doi:10.1007/s11255-017-1639-2 Wang J, Ai X, Li L, Gao Y, Sun N, Li C, Sun W (2017) Alprostadil protects type 2 diabetes mellitus patients treated with metformin from contrast-induced nephropathy. Int Urol Nephrol. doi:10.​1007/​s11255-017-1639-2
2.
Zurück zum Zitat Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39(5):930–936CrossRefPubMed Nash K, Hafeez A, Hou S (2002) Hospital-acquired renal insufficiency. Am J Kidney Dis 39(5):930–936CrossRefPubMed
3.
Zurück zum Zitat Firouzi A, Maadani M, Kiani R, Shakerian F, Sanati HR, Zahedmehr A, Nabavi S, Heidarali M (2015) Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol 47(3):521–525CrossRefPubMed Firouzi A, Maadani M, Kiani R, Shakerian F, Sanati HR, Zahedmehr A, Nabavi S, Heidarali M (2015) Intravenous magnesium sulfate: new method in prevention of contrast-induced nephropathy in primary percutaneous coronary intervention. Int Urol Nephrol 47(3):521–525CrossRefPubMed
4.
Zurück zum Zitat Bei W, Li H, Lin K (2017) Post-Hoc Study: intravenous Hydration Treatment in Chinese Patients with High Risk of Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. Sci Rep 7(3):45023CrossRefPubMedPubMedCentral Bei W, Li H, Lin K (2017) Post-Hoc Study: intravenous Hydration Treatment in Chinese Patients with High Risk of Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. Sci Rep 7(3):45023CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Song T, Song M, Ge Z (2017) Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty. J Interv Cardiol 30(3):281–285CrossRefPubMed Song T, Song M, Ge Z (2017) Comparison of the nephrotoxic effects of iodixanol versus iohexol in patients with chronic heart failure undergoing coronary angiography or angioplasty. J Interv Cardiol 30(3):281–285CrossRefPubMed
6.
Zurück zum Zitat Owen RJ, Hiremath S, Myers A (2014) Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J 65(2):96–105CrossRefPubMed Owen RJ, Hiremath S, Myers A (2014) Canadian Association of Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: update 2012. Can Assoc Radiol J 65(2):96–105CrossRefPubMed
7.
Zurück zum Zitat Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C (2010) Reactive oxygen species and the pathogenesis of radio contrast-induced nephropathy. Invest Radio 145(4):188–195CrossRef Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C (2010) Reactive oxygen species and the pathogenesis of radio contrast-induced nephropathy. Invest Radio 145(4):188–195CrossRef
8.
Zurück zum Zitat Liu YH, Jiang L, Chen JY, Tan N, Liu Y, He PC (2016) Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention? Int Urol Nephrol 48(10):1675–1682CrossRefPubMed Liu YH, Jiang L, Chen JY, Tan N, Liu Y, He PC (2016) Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention? Int Urol Nephrol 48(10):1675–1682CrossRefPubMed
9.
Zurück zum Zitat He P, Kawamura H, Takemoto M, Maezawa Y, Ishikawa T, Ishibashi R, Sakamoto K, Shoji M, Hattori A, YamagaM Ide S, Ide K, Hayashi A, Tokuyama H, KobayashiK Yokote K (2016) Combination ofcilostazol and probucol protected podocytesfromlipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms. J Nephroldoi. doi:10.1007/s40620-016-0361-y He P, Kawamura H, Takemoto M, Maezawa Y, Ishikawa T, Ishibashi R, Sakamoto K, Shoji M, Hattori A, YamagaM Ide S, Ide K, Hayashi A, Tokuyama H, KobayashiK Yokote K (2016) Combination ofcilostazol and probucol protected podocytesfromlipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms. J Nephroldoi. doi:10.​1007/​s40620-016-0361-y
10.
Zurück zum Zitat Zhang Q, Chen L, Si Z, Bu H, Narasimhulu CA, Song X, Cui MY, Liu H, Lu T, He G, Parthasarathy S, Cui L, Liu Z, Cui Y (2016) Probucol protects endothelial progenitor cells against oxidized low-density lipoprotein via suppression of reactive oxygen species formation in vivo. Cell Physiol Biochem 39(1):89–101CrossRefPubMed Zhang Q, Chen L, Si Z, Bu H, Narasimhulu CA, Song X, Cui MY, Liu H, Lu T, He G, Parthasarathy S, Cui L, Liu Z, Cui Y (2016) Probucol protects endothelial progenitor cells against oxidized low-density lipoprotein via suppression of reactive oxygen species formation in vivo. Cell Physiol Biochem 39(1):89–101CrossRefPubMed
11.
Zurück zum Zitat Lee HC, Sheu SH, Liu IH, Lee CC, Hsieh CC, Yen HW, Lai WT, Chang JG (2012) Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J Nephrol 25(1):56–62CrossRefPubMed Lee HC, Sheu SH, Liu IH, Lee CC, Hsieh CC, Yen HW, Lai WT, Chang JG (2012) Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J Nephrol 25(1):56–62CrossRefPubMed
12.
Zurück zum Zitat Navarese EP, Gurbel PA, Andreotti F, Kołodziejczak MM, Palmer SC, Dias S, Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M, Brockmeyer M, Airoldi F, Ruospo M, De Servi S, Wojakowski W, O’ Connor C, Strippoli GF (2017) Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS ONE 12(2):e0168726CrossRefPubMedPubMedCentral Navarese EP, Gurbel PA, Andreotti F, Kołodziejczak MM, Palmer SC, Dias S, Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M, Brockmeyer M, Airoldi F, Ruospo M, De Servi S, Wojakowski W, O’ Connor C, Strippoli GF (2017) Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS ONE 12(2):e0168726CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Toprak O (2017) Risk markers for contrast-induced nephropathy. Am J Med Sci 334(4):283–290CrossRef Toprak O (2017) Risk markers for contrast-induced nephropathy. Am J Med Sci 334(4):283–290CrossRef
14.
Zurück zum Zitat Su X, Xie X, Liu L, Lv J, Song F, Perkovic V, Zhang H (2017) Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and Bayesian network meta-analysis. Am J Kidney Dis 69(1):69–77CrossRefPubMed Su X, Xie X, Liu L, Lv J, Song F, Perkovic V, Zhang H (2017) Comparative effectiveness of 12 treatment strategies for preventing contrast-induced acute kidney injury: a systematic review and Bayesian network meta-analysis. Am J Kidney Dis 69(1):69–77CrossRefPubMed
15.
Zurück zum Zitat Pflueger A, Abramowitz D, Calvin AD (2009) Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit 15(6):125–136 Pflueger A, Abramowitz D, Calvin AD (2009) Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit 15(6):125–136
16.
Zurück zum Zitat Liu Y, Tan N, Zhou YL (2012) High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. J Nephrol 25(3):332–340CrossRefPubMed Liu Y, Tan N, Zhou YL (2012) High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention. J Nephrol 25(3):332–340CrossRefPubMed
17.
Zurück zum Zitat Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A, Daida H (2012) Probucol therapy improves long-term (> 10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis 220(2):463–469CrossRefPubMed Kasai T, Miyauchi K, Kubota N, Kajimoto K, Amano A, Daida H (2012) Probucol therapy improves long-term (> 10-year) survival after complete revascularization: a propensity analysis. Atherosclerosis 220(2):463–469CrossRefPubMed
18.
Zurück zum Zitat Liu J, Li M, Lu H, Qiao W, Xi D, Luo T, Xiong H, Guo Z (2015) Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis. PLoS ONE 10(4):e0124021CrossRefPubMedPubMedCentral Liu J, Li M, Lu H, Qiao W, Xi D, Luo T, Xiong H, Guo Z (2015) Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis. PLoS ONE 10(4):e0124021CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS (2009) Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Current Pharm Des 15(27):3094CrossRef Adameova A, Xu YJ, Duhamel TA, Tappia PS, Shan L, Dhalla NS (2009) Anti-atherosclerotic molecules targeting oxidative stress and inflammation. Current Pharm Des 15(27):3094CrossRef
20.
Zurück zum Zitat Yoshida M, Kimura H, Kyuki K, Ito M (2006) Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet. Eur J Pharmacol 48(1–3):174CrossRef Yoshida M, Kimura H, Kyuki K, Ito M (2006) Combined effect of probucol and insulin on renal damage in diabetic rats fed a high cholesterol diet. Eur J Pharmacol 48(1–3):174CrossRef
21.
Zurück zum Zitat Li G, Yin L, Liu T, Zheng X, Xu G, Xu Y, Yuan R, Che J, Liu H, Zhou L, Chen X, He M, Li Y, Wu L, Liu E (2009) Role of probucol in preventing contrast-induced acute kidney injury after coronary interventional procedure. Am J Cardiol 103(4):512CrossRefPubMed Li G, Yin L, Liu T, Zheng X, Xu G, Xu Y, Yuan R, Che J, Liu H, Zhou L, Chen X, He M, Li Y, Wu L, Liu E (2009) Role of probucol in preventing contrast-induced acute kidney injury after coronary interventional procedure. Am J Cardiol 103(4):512CrossRefPubMed
22.
Zurück zum Zitat Yin L, Li G, Liu T, Yuan R, Zheng X, Xu G, Xu Y, Che J, Liu X, Ma X, Li F, Liu E, Chen X, Wu L, Fan Z, Ruan Y, He M, Li Y (2013) Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial. Int J Cardiol 167(2):426–429CrossRefPubMed Yin L, Li G, Liu T, Yuan R, Zheng X, Xu G, Xu Y, Che J, Liu X, Ma X, Li F, Liu E, Chen X, Wu L, Fan Z, Ruan Y, He M, Li Y (2013) Probucol for the prevention of cystatin C-based contrast-induced acute kidney injury following primary or urgent angioplasty: a randomized, controlled trial. Int J Cardiol 167(2):426–429CrossRefPubMed
23.
Zurück zum Zitat Li H, Li X, Ma H, Wang Y, Fu N, Jin D, Cong H (2014) Atorpvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure. Sci W J. doi:10.1155/2014/565367 Li H, Li X, Ma H, Wang Y, Fu N, Jin D, Cong H (2014) Atorpvastatin combining with probucol: a new way to reduce serum uric acid level during perioperative period of interventional procedure. Sci W J. doi:10.​1155/​2014/​565367
24.
Zurück zum Zitat Börekçi A, Gür M, Türkoğlu C, Çaylı M, Selek Ş, KaypaklıO Uçar H, Coşkun M, Şeker T, Koç M, Gökdeniz T, Gözükara MY (2015) Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology 66(4):339–345CrossRefPubMed Börekçi A, Gür M, Türkoğlu C, Çaylı M, Selek Ş, KaypaklıO Uçar H, Coşkun M, Şeker T, Koç M, Gökdeniz T, Gözükara MY (2015) Oxidative stress and paraoxonase 1 activity predict contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Angiology 66(4):339–345CrossRefPubMed
25.
Zurück zum Zitat Jian-Wei Z, Yu-Jie Z, Shu-Jun C, Qing Y, Shi-Wei Y, Bin N (2014) Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology 65(5):402–407CrossRefPubMed Jian-Wei Z, Yu-Jie Z, Shu-Jun C, Qing Y, Shi-Wei Y, Bin N (2014) Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology 65(5):402–407CrossRefPubMed
26.
Zurück zum Zitat Wang N, Wei RB, Li QP, Yang X, Li P, Huang MJ (2015) Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism. Med Sci Monit 21:2886–2892CrossRefPubMedPubMedCentral Wang N, Wei RB, Li QP, Yang X, Li P, Huang MJ (2015) Renal Protective Effect of Probucol in Rats with Contrast-Induced Nephropathy and its Underlying Mechanism. Med Sci Monit 21:2886–2892CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Yen HW, Lee HC, Lai WT, Sheu SH (2007) Effects of acetylcysteine and probucol on contrast medium-induced depression of intrinsic renal glutathione peroxidase activity in diabetic rats. Arch Med Res 38(3):291–296CrossRefPubMed Yen HW, Lee HC, Lai WT, Sheu SH (2007) Effects of acetylcysteine and probucol on contrast medium-induced depression of intrinsic renal glutathione peroxidase activity in diabetic rats. Arch Med Res 38(3):291–296CrossRefPubMed
28.
Zurück zum Zitat Zhu H, Chen X, Cai G, Zheng Y, Liu M (2016) Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: a randomized double-blind placebo-controlled multicenter clinical study. J Diabetes 8(5):677CrossRefPubMed Zhu H, Chen X, Cai G, Zheng Y, Liu M (2016) Telmisartan combined with probucol effectively reduces urinary protein in patients with type 2 diabetes: a randomized double-blind placebo-controlled multicenter clinical study. J Diabetes 8(5):677CrossRefPubMed
Metadaten
Titel
The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study
verfasst von
Naikuan Fu
Shicheng Yang
Jing Zhang
Peng Zhang
Min Liang
Hongliang Cong
Wenhua Lin
Fengshi Tian
Chengzhi Lu
Publikationsdatum
25.10.2017
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 1/2018
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-017-1718-4

Weitere Artikel der Ausgabe 1/2018

International Urology and Nephrology 1/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.